Southeastern Section of the American Urological Association SES AUA 2025
SES AUA 2025 Prostate Cancer
- SES AUA 2025: Artificial Intelligence Applications in Prostate Cancer Diagnosis and Treatment
- SES AUA 2025: Overall Survival with Darolutamide Versus Placebo in Combination with Androgen Deprivation Therapy and Docetaxel Accounting for Subsequent Therapy: A Sensitivity Analysis from ARASENS
- SES AUA 2025: Early Longitudinal Outcomes of Black Men Undergoing PSA Screening Following Implementation of a PSA-Based Risk Stratification Algorithm in a Health System-Wide Initiative
- SES AUA 2025: Phase 1 Trial of Mevrometostat (PF-06821497), a Potent and Selective Inhibitor of EZH2, in CRPC
- SES AUA 2025: Outcomes of Men with High-Risk Biochemically Recurrent Prostate Cancer who Suspended Enzalutamide Monotherapy Treatment in the Phase 3 EMBARK Study
SES AUA 2025 Bladder Cancer
- SES AUA 2025: Evaluation of Systemic Therapy and Surgical Consolidation in Patients with Node Positive UTUC
- SES AUA 2025: Development and Initial Experience of a Dedicated Female Bladder Cancer Clinical Care Coordinator Role
- SES AUA 2025: Multicenter Experience with First-Line Intravesical Gemcitabine + Docetaxel versus BCG for high risk NMIBC
- SES AUA 2025: LEGEND: Phase 1/2 Study of Detalimogene Voraplasmid, a Novel, Investigational, Non-Viral Intravesical Gene Therapy for BCG-Unresponsive NMIBC with CIS
- SES AUA 2025: Association of Somatic Gene Mutations in Urothelial Cancer Based on Location in the Bladder
SES AUA 2025 Kidney Cancer
- SES AUA 2025: Germline Testing for Renal Cancers – How Age and Tumor Characteristics Affect Pathogenic Variants
- SES AUA 2025: Identifying Key Mutations Linked to Metastasis in Clear Cell Renal Cell Carcinoma: A GENIE Database Analysis
- SES AUA 2025: Systemic Therapy for Renal Cell Carcinoma with a Tumor Thrombus: Management and Outcomes from the Intercontinental Collaboration on Renal Cell Carcinoma Database